학술논문
Efficacy and Safety of Elexacaftor/Tezacaftor/Ivacaftor in Children 6 Through 11 Years of Age with Cystic Fibrosis Heterozygous for F508del and a Minimal Function Mutation A Phase 3b, Randomized, Placebo-controlled Study
Document Type
Article
Author
Mall, M.A.; Brugha, R.; Gartner, S.; Legg, J.; Moeller, A.; Mondejar-Lopez, P.; Prais, D.; Pressler, T.; Ratjen, F.; Reix, P.; Robinson, P.D.; Selvadurai, H.; Stehling, F.; Ahluwalia, N.; Arteaga-Solis, E.; Bruinsma, B.G.; Jennings, M.; Moskowitz, S.M.; Noel, S.; Tian, S.; Weinstock, T.G.; Wu, P.; Wainwright, C.E.; Davies, J.C.
Source
In: American Journal of Respiratory and Critical Care Medicine . (American Journal of Respiratory and Critical Care Medicine, 1 December 2022, 206(11):1361-1369)
Subject
Language
English
ISSN
15354970
1073449X
1073449X